Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

The third scenario, in which the booster dose was with the Pfizer vaccine, showed the highest percentages of effectiveness: 56.8% against symptomatic infections and 85.5% against severe cases.

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID ... administration errors and save time, which may ultimately improve vaccination campaign efficiency.

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Additionally, people’s immunity to particular strains of norovirus wane over time ... vaccines with similar technology show that antibodies can migrate: For instance, with Moderna’s Covid ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...